French drug maker Sanofi on Thursday announced a new three-year research collaboration agreement with the TB Alliance “to accelerate the discovery and development of novel compounds against tuberculosis,” RTTNews reports (9/20). “According to company material, the projects will explore a compound which researchers believe has potential to treat all forms of tuberculosis, investigate another class of natural derivatives that has shown ‘impressive’ activity against tuberculosis bacteria, and identify future candidates for development among chemical compounds in Sanofi’s collection,” the Center for Global Health Policy’s “Science Speaks” blog writes (Barton, 9/20). RTTNews notes, “Sanofi, which discovered rifampicin in the early 1960s, markets several anti-tuberculosis drugs” (9/20).
PlusNews examines the recently approved grants under the Global Fund to Fight AIDS, Tuberculosis and Malaria’s Transitional Funding Mechanism (TFM), stating, “Last week, the Fund announced that 45 new grant applications, from countries such as Burundi, Malawi and Swaziland, have been approved under the TFM.” The news service notes, “Almost 25 percent of this combined total will go towards [tuberculosis (TB)], which represents a significant increase from the average 16 percent of funds allocated for TB since the Global Fund was created in 2002, according to a StopTB Partnership statement released in response” to the fund’s announcement. PlusNews notes, “Unlike regular grants, which can run for up to five years, those awarded under the TFM will be limited to two years, by which time the fund is expected to have launched its new funding model” (9/4).
Secretary of State Hillary Clinton reflects on changes in U.S. global health diplomacy since taking office in this Global Health and Diplomacy opinion piece. “America had been leading the global health fight for decades,” but “we recognized that to sustain the impact of our work, we needed to change the way we did business,” she writes. “For example, while our agencies were providing tremendous leadership in isolation, they could still do more to collaborate effectively,” she writes, adding, “[W]e weren’t doing enough to coordinate our efforts with other donors or our partner countries,” and “we weren’t building sustainable systems to eventually allow our partner countries to manage more of their own health needs.” She says, “We were unintentionally putting a ceiling on the number of lives we could save.”
The Wall Street Journal examines global efforts to stop the spread of drug-resistant tuberculosis (TB) strains, stating, “Global health officials view the emergence of incurable cases of tuberculosis in India as a worrisome evolution in a trend they have been concerned and intensely frustrated about for years — the rise of drug resistant forms of tuberculosis around the world.” The newspaper notes that “last year, a Mumbai doctor reported several cases of TB resistant to the 12 most commonly used medicines,” and adds that “[a]s many as 4.8 percent of all tuberculosis cases are resistant to at least some available drugs, according to a recent study.” The newspaper discusses WHO guidelines to prevent the spread of TB and writes, “Lucica Ditiu, executive secretary of the Geneva-based Stop TB Partnership, an advocacy organization whose members include the World Health Organization, the CDC and others, says only localized action by the countries themselves will bring rates of drug-resistant TB down” (Shah/Anand/McKay, 9/7).
“This week, heads of state, celebrities and CEOs will attend U.N. Secretary General Ban Ki-moon’s ‘Every Woman, Every Child’ dinner in New York,” an event that “will highlight the amazing contribution of the Global Fund to Fight AIDS, Tuberculosis and Malaria to the health of women and children in developing countries,” Lucy Chesire, executive director and secretary to the board of TB ACTION Group, writes in the Huffington Post’s “The Big Push” blog. “Ten years ago, tackling HIV, tuberculosis [TB] and malaria seemed an almost impossible task. Today we can see the beginning of the end of these three killer diseases,” she continues, adding, “But to make these historic achievements possible we need sufficient resources available!”
Forbes features an interview with Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, in which she “discusse[s] her motivations for pursuing a career in international affairs and social change, her experience as a senior program officer at the [Bill & Melinda Gates Foundation], what lessons she learned during her time at Gates that are most applicable in her new executive role at Friends of the Global Fight, the current landscape of challenges and solutions, and the role of technology in accelerating progress.” In the interview, Derrick said, “The mobilization to defeat these diseases in the past decade has been stunningly successful. … But there is so much more that needs to be done. If we don’t muster the resources to keep up the fight, and all commit to doing our part in a time of constrained resources, we risk backsliding on the progress we’ve already invested in” (Kanani, 9/21).
“[W]hat will the day be like when we finally defeat AIDS, tuberculosis and malaria?” Arianna Huffington, president and editor-in-chief of the Huffington Post Media Group, asks in the Huffington Post’s “The Big Push” blog. “[W]ith the launch today of The Big Push campaign — co-sponsored by the Global Fund [to Fight AIDS, Tuberculosis and Malaria] and the Huffington Post — this might be more than a thought exercise … because the progress that’s been made against these diseases in only the last 10 years has been so staggering that we may actually be in sight of the day when no child is born with HIV, nobody dies of malaria and we stop the spread of tuberculosis,” she continues and provides some statistics.
“[O]ver the past month, [tuberculosis (TB)] has captured high-profile attention from the Washington Post, the New York Times, TIME, NPR, [Agence France-Presse] and other major media, generating big headlines about the rising challenge we face in tackling one of humanity’s oldest and most resilient infectious diseases,” Jan Gheuens, interim director of the Bill & Melinda Gates Foundation’s TB Program, writes in the foundation’s “Impatient Optimists” blog. “Why should we be concerned?” he asks. Gheuens says because the worldwide number of multidrug-resistant TB (MDR-TB) cases is growing; “it costs a lot of money to treat MDR-TB”; and “MDR-TB patients must go through two years of intensive treatment, including daily injections for the first six months.” He concludes, “What’s clear now, more than ever, is that making progress on TB will require a comprehensive approach that includes new and better approaches to diagnosis, treatment, and prevention” (9/6).
This post in the Center for Strategic and International Studies’ “Smart Global Health” blog examines drug-resistant tuberculosis (TB), stating, “[S]ince the recent outbreak of the so-called totally drug-resistant tuberculosis (TDR-TB) in India, TB has a new face.” The blog details what TDR-TB is, recaps how resistant strains of TB develop and suggests several ways in which the global health community should respond (Kramer, 1/25).
Al Jazeera examines how “[a] series of public-health campaigns, including more aggressive screening, have been credited with a drop in tuberculosis [TB] cases in Kenya” in this video report. “The screening and treatment program, regarded as one of the best in the developing world, is credited with taking the rate of TB infections in the East African country from a high of 116,000 in 2006 to 106,000 last year,” but not without “an economic and political price,” the news service reports. “For TB screening and treatment programs to be effective, supply chains for drugs and equipment and proper training for staff and administrative back-up must be in place,” Al Jazeera reports (Greste, 1/9).